Urology News and Research

Latest Urology News and Research

Watson third quarter net income increases 31% to $138.7 million

Watson Pharmaceuticals, Inc. today reported net revenue of $1.1 billion for the third quarter ended September 30, 2011, an increase of 23 percent when compared to $882.4 million in the third quarter 2010. On a non-GAAP basis, net income for the third quarter 2011 increased 31 percent to $138.7 million or $1.09 per diluted share, compared to $105.9 million or $0.85 per diluted share in the third quarter 2010.

1 Nov 2011

New method can reduce intrusive thoughts in men with prostate cancer

Men with prostate cancer are twice as likely to commit suicide, but a method where they put intrusive thoughts into words may reduce this risk, reveals research at the Sahlgrenska Academy at the University of Gothenburg, Sweden.

1 Nov 2011

New antibiotic regimes may increase infections after specific surgical procedures

The introduction of new antibiotic regimes to tackle hospital-acquired infections, such as C. difficile, must take into account the possibility of increased infections following specific surgical procedures.

31 Oct 2011

Massachusetts court awards injunction preventing Watson from selling Amphastar's generic LOVENOX

Watson Pharmaceuticals, Inc., today confirmed that the United States District Court for the District of Massachusetts has granted Momenta Pharmaceuticals, Inc. and Sandoz Inc.'s request for a preliminary injunction preventing Watson and Amphastar Pharmaceuticals, Inc. from marketing or selling Amphastar's Enoxaparin Sodium Injection, a generic equivalent to Sanofi-aventis' LOVENOX.

29 Oct 2011

Patients with ANCA-associated vasculitis harbor Flt1 protein that blocks blood vessel repair

In some kidney diseases, patients have high blood levels of a protein that blocks blood vessel repair, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

28 Oct 2011

Ferring reports on FDA approval of labeling supplement for EUFLEXXA to treat knee osteoarthritis

On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.

22 Oct 2011

Specific dopamine system gene variants linked to ADHD medication response in children

Children with certain dopamine system gene variants have an improved response to methylphenidate - the most commonly prescribed medication for Attention Deficit Hyperactivity Disorder - in a finding that could help eliminate the guesswork from prescribing effective medications for children with ADHD.

22 Oct 2011

Watson receives FDA approval for Androderm lower-dose formulations

Watson Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved its Androderm (testosterone transdermal system) 2 mg and 4 mg formulation.

21 Oct 2011

AAHPO honors BMC physician for medical contributions in the U.S., Armenia

Richard Babayan, MD, was honored recently by the Armenian American Health Professional Organization (AAHPO) for his exceptional contributions to medicine in both the United States and in Armenia.

21 Oct 2011

TJUH offers new optical imaging agent for bladder cancer detection

Thomas Jefferson University Hospital is one of a select number of medical centers nationwide—and currently the only one in the Northeast—offering a newly approved optical imaging agent for the detection of papillary cancer of the bladder in patients with known or suspected bladder cancer.

21 Oct 2011

Older men more likely to die from prostrate cancer

Contrary to common belief, men age 75 and older are diagnosed with late-stage and more aggressive prostate cancer and thus die from the disease more often than younger men, according to a University of Rochester analysis published online this week by the journal, Cancer.

20 Oct 2011

Many Americans do not have access to a 'medical home'

Many Americans do not have access to a "medical home"-a physician practice that is able to manage ongoing care for patients and coordinate care among specialists and other health care facilities, according to a University of Michigan Health System-led study.

19 Oct 2011

Dendreon initiates enrollment in DN24-02 Phase 2 trial for HER2 positive cancer

Dendreon Corporation today announced that the company has begun enrolling patients into a Phase 2 trial for DN24-02, Dendreon's investigational active cellular immunotherapy being evaluated for the treatment of HER2 positive cancer.

18 Oct 2011

Watson confirms patent challenge of generic Daytrana

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Methylphenidate Transdermal System, 10 mg/9 hrs, 15 mg/9 hrs, 20 mg/9 hrs, and 30 mg/9 hrs.

15 Oct 2011

EMKinetics initiates TranStim therapy pivotal trial for urge incontinence, overactive bladder

EMKinetics, Inc. announced today initiation of the TranStim Transdermal Neuromodulation System pivotal trial for patients suffering from urge incontinence and overactive bladder.

14 Oct 2011

University of Cape Town, UT Southwestern sign affiliation agreement

UT Southwestern Medical Center and the faculty of health sciences of the University of Cape Town in South Africa, signed a five-year affiliation agreement today to collaborate on faculty and student exchanges, joint research and training activities and other educational opportunities.

13 Oct 2011

High dose vitamin E supplements may raise risk of prostate cancer: Study

The chances of developing the disease rose by 17 per cent, even years after men stopped taking the vitamin, claim researchers. This comes right after the study which found women taking multivitamins and other supplements have an increased risk of dying.

13 Oct 2011

PSA test for prostate cancer may confuse: Experts debate its continued use

According to new research the PSA test for prostate cancer does more harm than good. This week, the United States Preventive Services Task Force is expected to announce its recommendation against routine testing for blood levels of prostate-specific antigen, the protein that can be a signal of prostate cancer.

11 Oct 2011

Selected prescription drugs contribute to 10% of lower urinary tract symptoms among men

Use of selected prescription medications, including antidepressants, antihistamines, bronchodilators, anticholinergics, sympathomimetics, and diuretics contribute to 10 percent of lower urinary tract symptoms among men according to a Kaiser Permanente study published in the Archives of Internal Medicine.

11 Oct 2011

LUGPA encourages men to speak out to preserve prostate cancer screenings

The Large Urology Group Practice Association (LUGPA), representing more than 1,800 urologists, encourages men to speak out to preserve prostate cancer screenings.

11 Oct 2011